Literature DB >> 10904231

Sleep in right hemispherectomized patients: evidence of electrophysiological compensation.

L McCormick1, T Nielsen, M Ptito, A Ptito, J G Villemure, C Vera, J Montplaisir.   

Abstract

OBJECTIVES: The goal of this study is to provide a better understanding of the role of the cortex in sleep's macro- and microstructure modulation.
METHODS: Sleep architecture and phasic events were investigated in 4 patients having undergone right functional or anatomical hemispherectomy and 8 control subjects. Between-groups differences were assessed using the Wilcoxon-Mann-Whitney test.
RESULTS: Findings provide evidence for overall similarity between patients' and control subjects' left hemispheric sleep architecture. In addition, results clearly indicate that it is possible to detect electrical activity over the operated side of a hemispherectomized patient's brain, even when resection of the hemi-cortex has been complete. Finally, findings provide evidence for similar left and right hemispheric relative spectral activities and for an increase in fast activity bands over the intact hemisphere in anatomical hemispherectomized patients.
CONCLUSIONS: This study provides evidence that right hemispherectomy does not produce significant sleep architecture alterations as recorded over the intact hemisphere. In addition, residual activity detected over the operated side in anatomical hemispherectomized patients is interpreted as resulting from volume conduction originating from generators located in the intact hemisphere. Finally, there is strong evidence for electrophysiological compensation in the intact hemisphere following complete resection of the contralateral hemi-cortex.

Entities:  

Mesh:

Year:  2000        PMID: 10904231     DOI: 10.1016/s1388-2457(00)00319-9

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  1 in total

Review 1.  Sleep, Circadian Rhythms, and Epilepsy.

Authors:  Joseph T Daley; Jennifer L DeWolfe
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.